Site search

Clear filter
2901 results for '' found
A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)
A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL) (COALITION) (NCT04914741)
/
COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic
COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic
/
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)
/
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in C
/
A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period
A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period
/
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing
/
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizum
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizum
/
A phase III multicentre blinded randomised controlled clinical non-inferiority trial of cryopreserved platelets vs. conventional liquid-stored platelets for the management of surgical bleeding (C
/
A global, multicenter, randomized, double-blind, doubledummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo
/
An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B (ACTRN12623000841673)
An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B (ACTRN12623000841673)
/
55 56 57 58 59